UK pharma group acquires Belgium’s EsoBiotec as it announces EU has approved Imfinzi lung cancer drug
Business live – latest updates
AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.
EsoBiotec, a small privately held firm founded four years ago in Mont-Saint-Guibert, develops in-vivo cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments provided in minutes rather than weeks.
About Author
More Stories
In the red: global wine sales fall to lowest levels since 1961
Uyghur rights group calls on hotel chains not to ‘sanitise’ China abuses in Xinjiang
China accuses UK politicians of ‘arrogance’ in British Steel row